The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition
…Category: Pharma Industry
… 
Drug manufacturer vendor Kalderos says it expects several companies to begin using its 340B Pay platform during the next three months.
Kalderos Expects its 340B Rebate Model
…
… Editor’s note—A cascade of breaking 340B news developments over the past seven days—Amgen’s orphan drug action, HRSA’s dispute resolution final rule, the hospital lawsuit against HHS, the state attorneys general letter to HHS and the new GAO report—forced us to
…
… 
… 
… 
… 
…